在非人灵长类动物中针对两种埃博拉病毒和马尔堡病毒的暴露后免疫疗法。
Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates.
机构信息
US Army Medical Research Institute of Infectious Diseases, 1425 Porter St, Frederick, MD, 21702, USA.
Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, MB, R3E 3R2, Canada.
出版信息
Nat Commun. 2019 Jan 10;10(1):105. doi: 10.1038/s41467-018-08040-w.
The 2013-2016 Ebola virus (EBOV) disease epidemic demonstrated the grave consequences of filovirus epidemics in the absence of effective therapeutics. Besides EBOV, two additional ebolaviruses, Sudan (SUDV) and Bundibugyo (BDBV) viruses, as well as multiple variants of Marburg virus (MARV), have also caused high fatality epidemics. Current experimental EBOV monoclonal antibodies (mAbs) are ineffective against SUDV, BDBV, or MARV. Here, we report that a cocktail of two broadly neutralizing ebolavirus mAbs, FVM04 and CA45, protects nonhuman primates (NHPs) against EBOV and SUDV infection when delivered four days post infection. This cocktail when supplemented by the anti-MARV mAb MR191 exhibited 100% efficacy in MARV-infected NHPs. These findings provide a solid foundation for clinical development of broadly protective immunotherapeutics for use in future filovirus epidemics.
2013-2016 年埃博拉病毒（EBOV）疾病疫情表明，在缺乏有效治疗方法的情况下，丝状病毒疫情会造成严重后果。除 EBOV 外，还有两种埃博拉病毒，即苏丹（SUDV）和本迪布焦（BDBV）病毒，以及多种马尔堡病毒（MARV）变体，也引发了高死亡率的疫情。目前的实验性埃博拉病毒单克隆抗体（mAb）对 SUDV、BDBV 或 MARV 无效。在这里，我们报告称，两种广泛中和埃博拉病毒 mAb（FVM04 和 CA45）的鸡尾酒疗法在感染后四天给药可保护非人灵长类动物（NHPs）免受 EBOV 和 SUDV 感染。当这种鸡尾酒疗法补充抗 MARV mAb MR191 时，在 MARV 感染的 NHPs 中表现出 100%的疗效。这些发现为临床开发用于未来丝状病毒疫情的广泛保护性免疫疗法提供了坚实的基础。
Zotero 插件